1. Academic Validation
  2. Pharmacogenomics and analogues of the antitumour agent N6-isopentenyladenosine

Pharmacogenomics and analogues of the antitumour agent N6-isopentenyladenosine

  • Int J Cancer. 2009 May 1;124(9):2179-85. doi: 10.1002/ijc.24168.
Francesca Colombo 1 F Stefania Falvella Loris De Cecco Monica Tortoreto Graziella Pratesi Pierangela Ciuffreda Roberta Ottria Enzo Santaniello Luigi Cicatiello Alessandro Weisz Tommaso A Dragani
Affiliations

Affiliation

  • 1 Department of Experimental Oncology and Laboratories, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Abstract

N(6)-isopentenyladenosine (i(6)A), a member of the Cytokinin family of plant Hormones, has potent in vitro antitumour activity in different types of human epithelial Cancer cell lines. Gene expression profile analysis of i(6)A-treated cells revealed induction of genes (e.g., PPP1R15A, DNAJB9, DDIT3, and HBP1) involved in the negative regulation of cell cycle progression and reportedly up-regulated during cell cycle arrest in stress conditions. Of 6 i(6)A analogues synthesized, only the 1 with a saturated double bond of the isopentenyl side chain had in vitro antitumour activity, although weaker than that of i(6)A, suggesting that i(6)A biological activity is highly linked to its structure. In vivo analysis of i(6)A and the active analogue revealed no significant inhibition of Cancer cell growth in mice by either reagent. Thus, although i(6)A may inhibit cell proliferation by regulating the cell cycle, further studies are needed to identify active analogues potentially useful in vivo.

Figures
Products